Prosecution Insights
Last updated: April 18, 2026
Application No. 18/481,808

ONE-POT, MULTI-COMPONENT MANUFACTURING METHOD FOR TETRAHYDROTHIENOPYRIDINE DERIVATIVES INCLUDING N-SUBSTITUTED AMINO ACIDS

Non-Final OA §102
Filed
Oct 05, 2023
Examiner
RAHMANI, NILOOFAR
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Molecules & Materials
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
2y 1m
To Grant
74%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
871 granted / 1128 resolved
+17.2% vs TC avg
Minimal -3% lift
Without
With
+-2.9%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
12 currently pending
Career history
1140
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
12.6%
-27.4% vs TC avg
§102
25.2%
-14.8% vs TC avg
§112
35.8%
-4.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1128 resolved cases

Office Action

§102
DETAILED ACTION Claims 1-18 are pending in the instant application. Applicant's election without traverse of group (I), claims 1-2, 5-10, 12, 15, 18, where in A is PNG media_image1.png 130 164 media_image1.png Greyscale in the reply filed on 03/16/2026 is acknowledged. The requirement is still deemed proper and is therefore made FINAL. Claims 1-2, 5-10, 12, 15, 18 in part wherein A is PNG media_image2.png 130 162 media_image2.png Greyscale are examined. Claims 3-4, 11, 13-14, 16-17 and the remaining subject matter of claims 1-2, 5-10, 12, 15, 18 are withdrawn per 37 CFR 1.142(b). 2. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-2, 5-10, 12, 15, 18 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kalinski et al., Synthesis (2008), (24), 4007-4011. Kalinski et al. discloses the instant process on page 4008, scheme 1 as follow: PNG media_image3.png 242 776 media_image3.png Greyscale , which is in 60O using THF as a solvent, and the bromic acid is selected from 4-chlorophenyl, which anticipates the instant process. Therefore, the instant claims are anticipated by Kalinski et al. Claims 1-2, 5-10, 12, 15, 18 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Gharib et al., Journal of Chemical Engineering and chemistry Research (2014), 1(1), 1-5. Gharib et al. discloses the instant process from the STN search as follow: PNG media_image4.png 426 812 media_image4.png Greyscale , which anticipates the instant process. Therefore, the instant claims are anticipated by Gharib et al. 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /NILOOFAR RAHMANI/ 04/03/2026
Read full office action

Prosecution Timeline

Oct 05, 2023
Application Filed
Apr 03, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595249
ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS
2y 5m to grant Granted Apr 07, 2026
Patent 12582718
INTEGRIN TARGETING LIGANDS AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577242
PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS
2y 5m to grant Granted Mar 17, 2026
Patent 12577245
SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS
2y 5m to grant Granted Mar 17, 2026
Patent 12570655
CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
74%
With Interview (-2.9%)
2y 1m
Median Time to Grant
Low
PTA Risk
Based on 1128 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month